Stocks
REGENXBIO Financial Statements (RGNX) |
||||||||||
| REGENXBIOsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2021 | 01.03.2022 | 31.12.2022 | 28.02.2023 | 27.02.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 154.6 | 470.3 | 112.7 | 112.7 | 90.2 | 84.3 | |||
| Operating Income, bln rub | -119.2 | 160.0 | -262.9 | -262.9 | -268.1 | -243.8 | ||||
| EBITDA, bln rub | ? | -96.8 | 169.5 | -257.0 | -244.2 | -239.5 | -225.1 | |||
| Net profit, bln rub | ? | -111.3 | 127.8 | -280.3 | -280.3 | -263.5 | -238.8 | |||
| OCF, bln rub | ? | -54.1 | 218.9 | -207.5 | -218.4 | -182.3 | ||||
| CAPEX, bln rub | ? | 26.9 | 84.2 | 30.7 | 9.96 | 2.48 | ||||
| FCF, bln rub | ? | -80.9 | 134.7 | -238.2 | -228.4 | -184.7 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 238.1 | 258.5 | 375.6 | 321.1 | 321.2 | 277.1 | ||||
| Cost of production, bln rub | 35.7 | 51.8 | 54.5 | 54.5 | 37.2 | 51.1 | ||||
| R&D, bln rub | 166.3 | 181.4 | 242.5 | 242.5 | 232.3 | 201.3 | ||||
| Interest expenses, bln rub | 0.771 | 26.3 | 23.3 | 23.3 | 6.86 | 4.61 | ||||
| Assets, bln rub | 708.2 | 1 114 | 833.3 | 833.3 | 574.0 | 519.1 | ||||
| Net Assets, bln rub | ? | 377.8 | 764.3 | 516.2 | 516.2 | 311.7 | 301.4 | |||
| Debt, bln rub | 72.7 | 86.7 | 94.8 | 94.8 | 89.3 | 84.1 | ||||
| Cash, bln rub | 475.7 | 457.4 | 364.6 | 364.6 | 275.3 | 255.5 | ||||
| Net debt, bln rub | -403.1 | -370.8 | -269.8 | -269.8 | -186.0 | -171.4 | ||||
| Ordinary share price, rub | 45.4 | 32.7 | 22.7 | 22.7 | 18.0 | 14.2 | ||||
| Number of ordinary shares, mln | 37.3 | 42.4 | 43.2 | 43.2 | 43.7 | 50.8 | ||||
| Market cap, bln rub | 1 691 | 1 388 | 979 | 979 | 785 | 720 | ||||
| EV, bln rub | ? | 1 288 | 1 017 | 709 | 709 | 599 | 549 | |||
| Book value, bln rub | 378 | 764 | 516 | 516 | 312 | 301 | ||||
| EPS, rub | ? | -2.98 | 3.01 | -6.50 | -6.50 | -6.02 | -4.70 | |||
| FCF/share, rub | -2.17 | 3.17 | 0.00 | -5.52 | -5.22 | -3.64 | ||||
| BV/share, rub | 10.1 | 18.0 | 12.0 | 12.0 | 7.13 | 5.93 | ||||
| EBITDA margin, % | ? | -62.6% | 36.0% | -228.0% | -216.7% | -265.4% | -266.9% | |||
| Net margin, % | ? | -72.0% | 27.2% | -248.7% | -248.7% | -292.0% | -283.2% | |||
| FCF yield, % | ? | -4.79% | 9.71% | 0.00% | -24.3% | -29.1% | -25.6% | |||
| ROE, % | ? | -29.5% | 16.7% | -54.3% | -54.3% | -84.5% | -79.2% | |||
| ROA, % | ? | -15.7% | 11.5% | -33.6% | -33.6% | -45.9% | -46.0% | |||
| P/E | ? | -15.2 | 10.9 | -3.49 | -3.49 | -2.98 | -3.02 | |||
| P/FCF | -20.9 | 10.3 | -4.11 | -3.44 | -3.90 | |||||
| P/S | ? | 10.9 | 2.95 | 8.68 | 8.68 | 8.70 | 8.54 | |||
| P/BV | ? | 4.48 | 1.82 | 1.90 | 1.90 | 2.52 | 2.39 | |||
| EV/EBITDA | ? | -13.3 | 6.00 | -2.76 | -2.90 | -2.50 | -2.44 | |||
| Debt/EBITDA | 4.16 | -2.19 | 1.05 | 1.10 | 0.78 | 0.76 | ||||
| R&D/CAPEX, % | 618.9% | 215.5% | 789.1% | 2 332% | 8 105% | |||||
| CAPEX/Revenue, % | 17.4% | 17.9% | 0.00% | 27.3% | 11.0% | 2.94% | ||||
| REGENXBIO shareholders | ||||||||||
